Reuters logo
Zynerba's cannabis-based gel succeeds in mid-stage study
September 28, 2017 / 10:48 AM / 3 months ago

Zynerba's cannabis-based gel succeeds in mid-stage study

Sept 28 (Reuters) - Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.

The U.S. drug developer’s shares jumped 31 percent to $8.11 in premarket trading. (Reporting by Manas Mishra in Benagluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below